AbbVie Receives U.S. FDA Approval of MAVYRET? (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks

Press/Media: Press / Media

PeriodAug 4 2017

Media coverage

2

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET? (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPharmacy Choice
    CountryUnited States
    Date8/4/17
    PersonsFred Poordad
  • Title8/3/17 - AbbVie Receives U.S. FDA Approval of MAVYRETâ?¢ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPharmacy Choice
    CountryUnited States
    Date8/4/17
    PersonsFred Poordad